Related Experiment Video
Updated: Jul 19, 2026
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Pediatric inflammatory bowel disease: clinical and therapeutic aspects
1Department of Pediatrics, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA. skuga@mcw.edu
Insights
Pediatric inflammatory bowel disease (IBD) management requires further research into novel diagnostics and treatments. Current serologic markers are not yet reliable for screening, but genetic testing aids in optimizing therapy and preventing toxicity.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease (IBD) Research
- Autism Spectrum Disorder Comorbidities
Background:
- Incidences of pediatric ulcerative colitis and Crohn disease show geographic variations.
- A unique inflammatory bowel disorder associated with gastrointestinal symptoms has been observed in children with autism.
- The optimal application of emerging diagnostic and therapeutic strategies for pediatric IBD remains unclear.
Purpose of the Study:
- To review current understanding and future directions in pediatric inflammatory bowel disease (IBD).
- To evaluate the utility of novel diagnostic markers and treatments in children.
- To highlight the need for further pediatric-specific research.
Main Methods:
- Review of epidemiologic data on pediatric IBD prevalence.
- Analysis of studies on serologic markers (ASCA, pANCA) for IBD diagnosis.
- Evaluation of genetic testing (TPMT, 6-MP metabolites) in IBD management.
- Assessment of pilot trials for newer immunomodulatory agents (infliximab, tacrolimus).
Main Results:
- Serologic markers lack sufficient sensitivity and specificity for routine pediatric IBD screening or diagnosis.
- Genetic testing for thiopurine methyl transferase and 6-mercaptopurine metabolites is valuable for optimizing treatment and identifying toxicity risks.
- Infliximab shows short-term efficacy and safety in pediatric Crohn disease refractory to conventional therapy.
- Tacrolimus trials for fulminant pediatric colitis yielded disappointing results.
Conclusions:
- Large, prospective, population-based pediatric studies are essential for validating noninvasive IBD screening tools.
- Genetic profiling aids in personalized therapeutic strategies for pediatric IBD patients.
- Further investigation into novel agents like infliximab is warranted, while others like tacrolimus require re-evaluation for specific pediatric IBD indications.
Abstract:
Epidemiologic data suggest that the incidences of pediatric ulcerative colitis and Crohn disease continue to evolve with geographic variations. One study suggests that children with autism have a unique inflammatory bowel disorder that is associated with gastrointestinal symptoms. The appropriate use of new diagnostic tests and novel treatments for inflammatory bowel disease (IBD) needs to be clarified in the pediatric population. Because of concerns regarding sensitivity and specificity, serologic markers measuring anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies cannot yet replace conventional diagnostic testing for screening or diagnosis of pediatric IBD. Large, prospective, pediatric population-based studies still need to be performed to ascertain their use as a noninvasive screening tool. Genetic studies using thiopurine methyl transferase and measurement of 6-mercaptopurine metabolites appear to be valuable for management of pediatric patients with IBD, in assisting clinicians in optimizing therapeutic response to 6-mercaptopurine, and in identifying individuals at increased risk for drug-induced toxicity. Newer immunomodulatory agents also are being explored in pediatric IBD. Open pilot trials of infliximab (Remicade; Centocor, Malvern, PA) for the treatment of children with Crohn disease that does not respond to conventional management have demonstrated short-term efficacy and safety. Trials of tacrolimus for treatment of fulminant colitis in children have been disappointing.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:26Inflammatory Bowel Disease I: Introduction
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...